<unk>  or<unk><unk>  in myeloproliferative neoplasms include BLU-285, JQ1, and suberoyl anilide hydroxamic acid. Each of these<unk>  agents carries a unique mechanism of action on myeloid cells. The agents are currently in clinical trials.
Myeloproliferative neoplasm future or investigational therapies
Chronic myelogenous leukemia medical therapy
Chronic lymphocytic leukemia medical therapy
Acute myeloid leukemia medical therapy
Myeloproliferative neoplasm medical therapy
Aplastic anemia primary prevention
Myelodysplastic syndrome primary prevention
Chronic myelogenous leukemia primary prevention